Equity Instruments (Tables)

9 Months Ended

Mar. 31, 2015

Summary of Stock-Based Compensation Expense

The following table summarizes stock-based compensation expense for the three and nine months ended March 31, 2015 and 2014:


	Three Months Ended March 31,					Nine Months Ended March 31,
	2015		2014			2015		2014
Research and development expenses Stock options
Luoxis option plan	$	107,000	$	52,000		$	297,000	$	155,000
Vyrix option plan		8,000		29,000			26,000		29,000
General and administrative expenses Stock options
Luoxis option plan		138,000		58,000			371,000		116,000
Vyrix option plan		19,000		(55,000	)		56,000		85,000

	$	272,000	$	84,000		$	750,000	$	385,000

Unrecognized expense at March 31, 2015
Luoxis option plan	$	1,129,000
Vyrix option plan	$	194,000
Weighted average remaining years to vest
Luoxis option plan		2.23
Vyrix option plan		1.79

Warrants Issued in Conjunction with its Senior Convertible Debentures

Rosewind issued warrants in conjunction with the closing of its 2013 private placement. A summary of all warrants is as follows:


	Number of Warrants		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life
Outstanding June 30, 2014		465,250	$	1.00		3.92
Warrants exercised - Private/Registered Direct Placements		—

Outstanding March 31, 2015		465,250	$	1.00		3.17

Luoxis Diagnostics [Member]

Stock Option Activity

Pursuant to the Luoxis 2013 Stock Option Plan, 5.0 million shares of its common stock were reserved for issuance. Stock option activity is as follows:


	Number of Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life		Aggregate Fair Value
Outstanding June 30, 2014		1,950,000	$	1.00		9.01	$	1,374,000

Granted		885,000	$	1.60
Exercised		—	$	—
Forfeited/Cancelled		—	$	—

Outstanding March 31, 2015		2,835,000	$	1.19		8.61	$	2,541,000

Exercisable at March 31, 2015		937,500	$	1.00		8.26	$	687,000

Available for grant at March 31, 2015		2,165,000

Vyrix Pharmaceuticals [Member]

Stock Option Activity

Pursuant to the Vyrix 2013 Stock Option Plan, 5.0 million shares of its common stock were reserved for issuance. Stock option activity is as follows:


	Number of Options		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life		Aggregate Fair Value
Outstanding June 30, 2014		950,000	$	0.70		9.54	$	417,000

Granted		—	$	—
Exercised		—	$	—
Forfeited/Cancelled		—	$	—

Outstanding March 31, 2015		950,000	$	0.70		8.79	$	417,000

Exercisable at March 31, 2015		475,000	$	0.70		8.79	$	208,000

Available for grant at March 31, 2015		4,050,000

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References+ Details